Effect of switching recombinant human growth hormone: Comparative analysis of phase 3 clinical data
Autor: | Mieczysław Szalecki, Mieczysław Walczak, Markus Zabransky, Sigrid Balser, Tomasz Romer |
---|---|
Rok vydání: | 2011 |
Předmět: |
Omnitrope
safety recombinant human growth hormone (rhGH) medicine.medical_specialty Study groups Demographics efficacy immunogenicity law.invention Growth hormone deficiency children law Internal medicine Medicine Drug reaction growth hormone deficiency (GHD) Original Research General Environmental Science switching business.industry genotropin Human growth hormone Genotropin medicine.disease Current analysis Endocrinology Recombinant DNA General Earth and Planetary Sciences business |
Zdroj: | Biologics in Therapy |
ISSN: | 2190-9164 |
Popis: | Introduction Recombinant human growth hormone (rhGH) is effective and safe when used to treat growth hormone deficiency (GHD) in children. However, it has been suggested that switching between different types of rhGH can have a detrimental effect on patients. Methods The current analysis assessed the efficacy and safety of rhGH in children who received continuous Omnitrope® (Sandoz GmbH, Kundl, Austria) therapy either with lyophilized powder for solution or ready-to-use solution, with children who received 9 months of treatment with Genotropin® (Pfizer Limited, Sandwich, UK) followed by Omnitrope solution thereafter. Changes to height, height SD score (SDS), height velocity SDS, insulin-like growth factor (IGF-1) levels, and IGF binding protein (IGFBP-3) levels were assessed using data from three trials. Results Baseline demographics of the three study groups were similar. Over an 18-month period there were no observable differences between the three groups with respect to height, height SDS, height velocity SDS, IGF-1 levels, and IGFBP-3 levels. This result was corroborated by the model data, whereby most data points for Omnitrope-treated children fell within the defined limits of the prediction model based on Genotropin data. Few adverse drug reactions (ADRs) occurred. Conclusions Switching from Genotropin to Omnitrope solution has no impact on efficacy or safety in children with GHD, and the various rhGH preparations are well tolerated. |
Databáze: | OpenAIRE |
Externí odkaz: |